Bispecific antibody · Immune activation, directed at PD-1 (PDCD1) and VEGF-A · developed by Crescent Biopharma
CR-001 is a tetravalent anti-PD-1/anti-VEGF-A bispecific antibody, built from a bivalent Fc-silenced IgG1 against VEGF-A with two PD-1-targeting single chain variable fragments fused to its C-terminus. It blocks PD-1 engagement by PD-L1 and PD-L2 to enhance T-cell tumor killing, and blocks VEGF-A binding to VEGFR1 and VEGFR2 to inhibit angiogenesis. It is studied in locally advanced or metastatic solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07335497 | Phase 1/2 | Locally Advanced / Metastatic Solid Tumors | Recruiting | CBIO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Locally Advanced / Metastatic Solid Tumors
See CBIO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CBIO catalysts and pipeline →